-
Innovation Ranking
Innovation Ranking – ARB Corporation Ltd
ARB Corporation Ltd (ARB) is a retailer of automobile parts and accessories. The company offers products such as protective equipment, vehicle lighting, old man emu 4x4 suspension, canopies and Ute lids, drawers and cargo barriers, roof racks and roof bars, long-range tanks, recovery equipment, air lockers and accessories, ARB compressors, camping accessories, portable fridge freezers; battery, power and 12V solar solutions and general accessories. It offers ARB compressors such as high output compressors, twin compressors, air locker activation systems and...
-
Sector Analysis
NewResistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Resistant Hypertension (RH) Marketed and Pipeline Drugs Report Overview Resistant Hypertension (RH) refers to high blood pressure (BP) that is above the target level in a patient. This occurs even when they are taking three different classes of antihypertensive medications concurrently. These medication classes typically include diuretics, long-acting calcium channel blockers, and renin-angiotensin system blockers (ACEs or ARBs). The Resistant Hypertension (RH) marketed, and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabotamig in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabotamig in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabotamig in Gastric Cancer Drug Details: Cabotamig (ARB-202) is under development for...
-
Company Insights
Innovation and Patenting activity of ARB Corporation Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ARB Corporation Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARB-202 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARB-202 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARB-202 in Pancreatic Cancer Drug Details:ARB-202 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARB-202 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARB-202 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARB-202 in Colorectal Cancer Drug Details:ARB-202 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARB-202 in Gastrointestinal Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARB-202 in Gastrointestinal Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARB-202 in Gastrointestinal TumorDrug Details:ARB-202 is under development for the treatment of refractory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARB-202 in Metastatic Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARB-202 in Metastatic Liver Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARB-202 in Metastatic Liver CancerDrug Details:ARB-202 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARB-202 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARB-202 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARB-202 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details:ARB-202 is under development...